Jacob B. Allred

Pomalidomide (CC4047) Plus Low-Dose Dexamethasone As Therapy for Relapsed Multiple Myeloma

Martha Q. Lacy, Suzanne R. Hayman, Morie A. Gertz et al. · Journal of Clinical Oncology · 2009 · 320 citations

Medicine, Pharmacology, Pharmacotherapy +16

The activity of lenalidomide with or without dexamethasone in patients with primary systemic amyloidosis

Angela Dispenzieri, Martha Q. Lacy, Steven R. Zeldenrust et al. · Blood · 2006 · 272 citations · Full text

Life Sciences, Immunology, Pharmacotherapy +5

Lenalidomide therapy in myelofibrosis with myeloid metaplasia

Ayalew Tefferi, Jörge E. Cortes, Srđan Verstovšek et al. · Blood · 2006 · 252 citations · Full text

Medicine, Hematology, Oncology +13

Pomalidomide plus low-dose dexamethasone in myeloma refractory to both bortezomib and lenalidomide: comparison of 2 dosing strategies in dual-refractory disease

Martha Q. Lacy, Jacob B. Allred, Morie A. Gertz et al. · Blood · 2011 · 221 citations

Medicine, Oncology, Pharmacotherapy +16

Pomalidomide (CC4047) plus low dose dexamethasone (Pom/dex) is active and well tolerated in lenalidomide refractory multiple myeloma (MM)

Martha Q. Lacy, Suzanne R. Hayman, Morie A. Gertz et al. · Leukemia · 2010 · 198 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +12